The scope of Sanofi Pasteur’s Research & Development activities is vast and complex, encompassing the entire chain of events before a new vaccine becomes available – from understanding a disease and its biological foundations, to clinical development and testing, to obtaining health authorities’ approval for marketing the new vaccine.
We have currently vaccines in development or submitted for approval to meet the specific needs of different segments of the population (influenza, vaccines combination, etc.) or unmet medical needs (respiratory syncytial virus, etc.).
| PHASE I | PHASE II | PHASE III | REGISTRATION | |||
|
Herpes Simplex Virus Type 2
HSV-2 therapeutic vaccine (1) |
Tdap US
Tdap booster |
MenQuadfiTM
Meningococcal ACYWConjugate vaccine, US/EU 6w+ |
Fluzone® QIV HD
Quadrivalent inactivated influenza vaccine – High dose |
|||
|
Respiratory syncytial virus
Infants 4-month and older vaccinesGet more information |
HIV
Viral vector prime & rgp120 boost vaccine |
Pediatric pentavalent vaccine
DTP-Polio-Hib Japan |
MenQuadfiTM
Meningococcal ACYWConjugate vaccine, US 2y+, EU 1y+ |
|||
|
Pneumococcal Conjugate Vaccine (PCV) (2)
|
Shan 6
DTP-HepB-Polio-HibPediatric hexavalent vaccine |
|||||
|
VerorabVax® (VRVg) Purified vero rabies vaccine
|
||||||
|
nirsevimab (3)
Respiratory syncytial virusMonoclonal antibodyGet more information |
| New molecular entities | Additional indications | Publication date: october 2019 |
(1) Developed in collaboration with Immune Design/Merck
(2) Developed in collaboration with SK
(3) Developed in collaboration with AstraZeneca
Related article
